Sichuan Baili Pharmaceutical Co., Ltd.

This study tests whether adding a new drug called BL-B01D1 to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that can be removed with surgery. About 90 participants will recei…

This early-phase trial is testing a new drug called BL-M07D1 in people with advanced HER2-positive or low-expression breast cancer and other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then testing that…

This study tests a new combination of drugs (BL-B01D1 and tislelizumab) against standard chemotherapy plus tislelizumab as the first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer. About 562 adults with good performance status will join th…

This Phase 3 trial tests a new drug, BL-M07D1, against standard chemotherapy in about 400 people with a specific type of advanced bile duct cancer (HER2-positive) that has stopped responding to platinum-based chemo. The goal is to see if BL-M07D1 can help people live longer. Part…

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 538 people with advanced biliary tract cancer that has worsened after prior treatments. The goal is to see if the new drug helps people live longer. The study is not yet recruiting.

This phase II trial is testing whether combining an experimental drug called BL-B01D1 with a PD-1 inhibitor can shrink tumors in people with advanced or metastatic urothelial carcinoma (a type of bladder cancer) who have not had prior systemic therapy. The study will measure how …

This study tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) in people with advanced lung cancer, nasopharyngeal cancer, or other solid tumors that have spread. The goal is to see if the combination can shrink tumors and control the disease. About 57…

This trial is testing an experimental drug called BL-M07D1 in people with a specific type of advanced non-small cell lung cancer that has a HER2 mutation. The study aims to find the best dose and see how well the drug shrinks tumors, while also checking for side effects. Particip…

This phase 3 trial compares an experimental drug called BL-B01D1 to standard chemotherapy in people with a common type of breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and cannot be removed by surgery. The study aims to see if BL-B01D1 can delay cancer …

This phase II trial is testing whether a combination of an experimental drug (BL-B01D1) and a PD-1 monoclonal antibody can shrink tumors in people with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal type) and other solid tumors. The study enroll…

This phase II trial is testing whether combining an experimental drug called BL-B01D1 with a PD-1 monoclonal antibody can shrink tumors in people with extensive-stage small cell lung cancer. The study enrolls 66 adults aged 18 to 75 who have newly diagnosed, advanced disease. Res…

This phase II trial is testing whether combining BL-B01D1, a targeted drug, with a PD-1 monoclonal antibody can shrink tumors in people with advanced triple-negative breast cancer that cannot be surgically removed or has spread. The study enrolls about 52 adults aged 18 to 75 who…

This study tests a new combination of drugs (BL-B01D1 plus tislelizumab, with or without chemotherapy) as a first treatment for people with advanced esophageal cancer that cannot be removed by surgery. About 90 participants will be randomly assigned to receive either the new comb…

This phase 1 trial tests a new drug called GNC-038, a tetra-specific antibody designed to target multiple pathways involved in lupus. The study includes adults with moderate to severe lupus who are on stable standard treatment. Researchers are evaluating the drug's safety, tolera…

This Phase 3 trial tests a new drug called BL-M05D1 against standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). The study will include 438 adults who have already tried one prior treatment. The goal is …

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 384 women with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatment. The goal is to see if BL-B01D1 can slow disease progression and impro…

This early-phase trial tests a new drug called SI-B036, a bispecific antibody, in 31 adults with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants receive the drug by IV every 3 we…

This study tests a new drug called BL-B01D1, alone or with other cancer drugs, in 74 people with advanced liver cancer that has spread. The goal is to see if these combinations can shrink tumors and how safe they are. Participants will receive the drugs through an IV or as pills …

This early-stage study tests a new drug called BL-M24D1 in about 33 adults with multiple myeloma or other blood cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug helps control the disease. Particip…

This phase 3 trial tests whether a new drug, BL-M07D1, combined with pertuzumab works better than the current standard treatment (docetaxel, trastuzumab, and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. About 596 women aged 18-75 who have …

This early-stage study tests a new drug called BL-ARC002 in 22 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the drug…

This phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in about 508 adults with advanced bladder cancer that has worsened after prior treatments. The goal is to see if the new drug can slow cancer growth or improve survival. Participants will receive ei…

This phase 3 trial is testing whether adding an experimental IV drug called BL-B01D1 to the standard pill osimertinib works better than osimertinib alone for people with advanced EGFR-mutated non-small cell lung cancer. About 720 participants will be randomly assigned to one of t…

This early-phase study tests a new drug called BL-M08D1 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps shrink tumors. About 22 adults will take part in th…

This study tests a new drug called BL-M07D1 in people with advanced HER2-positive or HER2-low urinary and digestive tract cancers. The first part finds a safe dose; the second part checks if the drug can shrink tumors. About 42 adults aged 18–75 will take part.

This study tests a combination of two drugs, BL-M07D1 and pembrolizumab, in people with advanced non-squamous non-small cell lung cancer that has high levels of a protein called HER2. The goal is to see if the combination shrinks tumors and how safe it is. About 80 adults aged 18…

This early-phase study tests a new drug called BL-M24D1 in 33 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the right dose, and get a first look at whether the drug shrinks tumors. Participants receive the d…

This Phase II trial is testing whether two experimental drugs (SI-B001 and SI-B003) plus standard chemotherapy can help people with head and neck cancer that has come back or spread. About 60 adults aged 18 to 75 will receive the combination as their first treatment. The main goa…

This early-phase study tests a new drug called GNC-077 in 20 adults with advanced breast cancer or other solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive the drug by injection, and r…

This early-stage trial is testing a new drug called GNC-077, a multi-specific antibody, in 20 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see how the body processes…

This Phase I trial is testing a new drug called BL-M17D1 in 20 people with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it shrinks tumo…

This Phase II study tests a combination of three drugs—BL-B01D1, pembrolizumab, and possibly bevacizumab—in people whose cervical or endometrial cancer has come back or spread. The goal is to see if the combo shrinks tumors and to find the best dose. About 96 adults aged 18–75 wi…

This phase 3 trial tests whether a new drug, BL-M07D1, works better than the current standard (T-DM1) for people with HER2-positive breast cancer that still has invasive cancer after initial chemotherapy. About 1,450 women aged 18-75 will be randomly assigned to one of the two tr…

This study tests a new drug called BL-M07D1 against standard chemotherapy in 566 adults with HER2-low breast cancer that has come back or spread. The goal is to see if BL-M07D1 can slow the cancer's growth better than current treatments. Participants must be women aged 18 to 75 w…

This early-stage trial is testing an experimental drug called BL-M08D1 in 22 adults with relapsed or refractory lymphoid malignancies (cancers of the lymph system that have come back or not responded to treatment). The drug is given by IV every 3 weeks. The main goals are to chec…

This early-phase study tests a radioactive drug called lutetium BL-ARC001 in 22 people with advanced lung, breast, head and neck, or other solid tumors that have stopped responding to standard therapies. The drug is given by IV infusion over a 6-week cycle. The main goals are to …

This early-stage trial tests a new radioactive drug, lutetium BL-ARC001, in 22 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants receive the d…

This early-phase study tests a new drug called BL-M24D1 in people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 16 adults aged 18 to 75 will ta…

This early-phase trial is testing an experimental drug called BL-M24D1 in 33 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it can shrink tu…

This study tests a new drug (BL-B01D1) combined with a standard targeted therapy (TKI), with or without an immunotherapy (pembrolizumab), in 260 adults with advanced kidney cancer that has spread. The goal is to see if these combinations shrink tumors and are safe. Participants m…

This phase 3 trial tests a new drug called BL-M07D1 against standard chemotherapy in 490 people with HER2-positive advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. The study aims to see if BL-M07D1 helps people live longer or slows c…

This Phase 3 trial is testing a new drug called BL-M07D1 against standard chemotherapy (pembrolizumab plus platinum chemo) as a first treatment for people with advanced or metastatic non-squamous non-small cell lung cancer that has a HER2 mutation. About 440 participants will be …

This study tests a new drug called GNC-035 in 40 adults with non-Hodgkin lymphoma that has returned or not improved after standard therapy. The drug is a tetra-specific antibody designed to attack cancer cells in multiple ways. The goal is to find a safe dose and see if it can sh…

This study tests a new drug called BL-M07D1, given alone or with pertuzumab, against the standard treatment (taxane + trastuzumab and pertuzumab) for HER2-positive breast cancer before surgery. About 120 women with stage II-III breast cancer will participate. The goal is to see i…

This study tests a new drug called GNC-038, a tetra-specific antibody designed to target cancer cells in people with Non-Hodgkin's lymphoma that has come back or not responded to treatment. About 40 adults will receive the drug by IV to see if it is safe and can shrink tumors. Th…

This early-phase study tests a new drug called GNC-039 in people with advanced solid tumors, including a type of brain cancer called glioma, that have come back or spread. The main goals are to check the drug's safety, find the best dose, and see if it can help control the diseas…

This early-phase study tests a new drug called BL-B01D1 in 36 adults with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for early signs of tumor shrinkage. Participants will be closely…

This study tests two experimental drugs, SI-B001 and SI-B003, given together with or without chemotherapy in 160 people with advanced non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the combination shrinks tumors. Participants must …

This study tests an experimental drug called BL-B01D1 in people with advanced gynecological cancers or other solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. About 38 adults aged 18 to 75 wi…

This phase II trial tests two drugs, SI-B003 and BL-B01D1, alone or together in 121 adults with advanced non-small cell lung cancer or nasopharyngeal carcinoma. The goal is to see if the combination shrinks tumors and to find the safest, most effective dose. Participants must hav…

This early-stage trial tests a new drug called BL-B01D1 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, to find a safe dose, and second, to check how well that dose works and how the body handles it. About 570 p…

This phase II trial tests two experimental drugs, SI-B003 and BL-B01D1, in people with advanced HER2-negative breast cancer that has not responded to standard treatments. The study will see if the drugs can shrink tumors and determine the best dose. About 58 participants will rec…

This early-stage study tests a new drug, BL-M07D1, in about 26 people with advanced digestive tract or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Particip…

This Phase II trial is testing a drug called BL-B01D1 in 76 adults with advanced urinary system or other solid tumors that have not responded to standard treatments. The study aims to find the best dose and see how well the drug shrinks tumors, while also monitoring safety and si…

This study tests two experimental drugs, BL-B01D1 and SI-B003, alone or together in people with extensive-stage small cell lung cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the disease. About 100 adults aged 18 to 75 with good performan…

This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in people with advanced bladder cancer or other solid tumors that have not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. About 52…

This phase II trial tests two experimental drugs, BL-B01D1 and SI-B003, alone or together, in 130 women with recurrent or metastatic cervical cancer that hasn't responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Part…

This study tests a new combination of two drugs (SI-B001 and SI-B003) with or without chemotherapy in people with advanced head and neck cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the treatment can shrink tumors. About 130 adults a…

This study tests an experimental drug called BL-M07D1 in people with HER2-positive gynecologic cancers (like ovarian or uterine) that have come back or spread and no longer respond to standard treatments. About 138 participants will receive the drug to see if it can shrink tumors…

This phase II study is testing whether a new drug called SI-B003, alone or combined with BL-B01D1 or a PD-1 antibody, can shrink tumors in people with advanced esophageal, gastric, or colorectal cancer. About 376 participants will receive the treatments intravenously every three …

This early-phase study tests a new drug called BL-B01D1 in people with advanced stomach or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any side effects. About 96 adults aged 18 to 75 will take part, and r…

This early-stage trial tests a new drug called BL-M11D1 in 130 adults whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Participants must have a specific marker (CD33) on their leu…

This study tests two experimental drugs, BL-B01D1 and SI-B003, given alone or together, in people with head and neck cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or slow the disease. About 186 adults aged 18 to 75 who have tried at…

This early-phase study tests a new drug called BL-B16D1 in about 21 adults with recurrent or metastatic head and neck squamous cell carcinoma or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, a…

This early-phase study tests a new drug called BL-M14D1 in 22 adults with advanced small cell lung cancer, neuroendocrine tumors, or other solid cancers that have not responded to standard treatments. The drug is given by IV every 3 weeks. The main goals are to check safety, find…

This early-phase study tests a new drug called BL-M17D1 in 20 people with advanced HER2-positive gastrointestinal cancers (like stomach, pancreas, or colon cancer) or other solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether the …

This early-stage trial is testing a new drug called BL-B16D1 in 21 people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The main goals are to check safety, find the right dose, and get …

This early-phase study tests an experimental drug called BL-B16D1 in 21 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The main goals are to check safety, find the right dose, and get a first look at wh…